WO2016137513A1 - Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide - Google Patents
Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide Download PDFInfo
- Publication number
- WO2016137513A1 WO2016137513A1 PCT/US2015/018146 US2015018146W WO2016137513A1 WO 2016137513 A1 WO2016137513 A1 WO 2016137513A1 US 2015018146 W US2015018146 W US 2015018146W WO 2016137513 A1 WO2016137513 A1 WO 2016137513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- rosacea
- selenium sulfide
- micro
- skin
- Prior art date
Links
- 229960005265 selenium sulfide Drugs 0.000 title claims abstract description 29
- 201000004700 rosacea Diseases 0.000 title claims abstract description 24
- 241001303601 Rosacea Species 0.000 title claims abstract description 23
- 206010015150 Erythema Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 19
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 title claims abstract 7
- 239000000203 mixture Substances 0.000 title claims description 29
- 238000011282 treatment Methods 0.000 title abstract description 15
- 230000000699 topical effect Effects 0.000 title description 7
- 231100000321 erythema Toxicity 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 229940110456 cocoa butter Drugs 0.000 claims description 5
- 235000019868 cocoa butter Nutrition 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 description 23
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 238000011010 flushing procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229940126702 topical medication Drugs 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000009736 adult acne Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940053636 finacea Drugs 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940086207 head & shoulders Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229940051736 rosadan Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910000338 selenium disulfide Inorganic materials 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention relates to the treatment of Rosacea and skin erythema, in general, and to a method utilizing a topical composition employing selenium sul fide of different concentrations depending on the severity and extent of user symptoms, in particular.
- Rosacea is a very common red, acne-like benign skin condition that affects approximately 45 million people worldwide. Its main symptoms include red or pink facial skin, small dilated blood vessels, small red bumps sometimes containing pus, cysts, and pink or irritated eyes. Characteristically involving the central region of the face (mainly the forehead, the cheeks, the chin, and the lower half of the nose), Rosacea is considered a chronic, long-term incurable skin condition with periodic ups and downs. Tending to occur more frequently in women, but more severely in men, Rosacea strikes both at potentially all ages. Unfortunately, emotional factors such stress, fear, anxiety and embaiTassment have been determined to ag g ravate the condition.
- Rosacea While lacking evidence that Rosacea can be spread by contact with the skin, the sharing of towels, or through inhalation, left untreated, the condition tends to worsen over time. Often being mistaken for acne, an allergic reaction, or other skin problems, its signs and symptoms may flair up for a period of weeks to months, and then diminish before flaring up again. Often aggravated by flushing, the redness in Rosacea may cause small blood vessels in the face to enlarge permanently and become more visible through the skin, appearing like tiny red lines. Continual or repeated episodes of flushing and blushing may promote inflammation, causing small red bumps often resembling teenage acne.
- selenium sulfide as an active ingredient in the method of treatment of Rosacea.
- having the chemical formula SS and also available as selenium disulfide S S , and selenium hexasiilfide S S , e' e 2 e &' selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis.
- selenium sul fide has been shown to be one in a class of anti -infectives that slow the growth of yeast which can lead to itching and flaking of the scalp.
- selenium sulfide is combined with a cocoa butter moisturizer carrier in the treatment of the Rosacea.
- the selenium sulfide is employed as the sole active ingredient in the treatment.
- Selenium sulfide is currently employed in a concentration of 1 % i n such dandruff shampoos as Seisun Blue®, Exsel® lotion shampoo, Glo-Sel®, and Head & Shoulders®
- composition of the invention may comprise all pharmaceutical forms for administration including solutions, gels, lotions and creams— as well as ointments, foams, emulsions, micro-emulsions, milks, serums, aerosols, sprays, dispersions, micro-capsules and micro-particles thereof.
- Acceptable carriers for the selenium sulfide are those suitable for topical applications for the skin, will not cause any safety or toxicity concerns, and wi l l be compatible with the selenium sulfide.
- One such earner employed successfully with the selenium sulfide has been found to be cocoa butter, an edible vegetable fat extracted from the cocoa bean.
- a ratio of about 3 parts cocoa butter to 1 part selenium sulfide provided almost optimum results in effectiveness to decrease the erythema resulting from Rosacea. Also utilizable as soaps and cleansing bars, a 1 % concentration of selenium sulfide ingredient has been approved by the FDA for cover-the-counter sales— and thus more readily obtainable, and at a lesser cost than other prescription medications used to treat these skin conditions. Effective in most instances of Rosacea, more resistant situations can be resolved by increasing the selenium sulfide concentrations to 2%, 3% or 4% levels; obtainable in the later percentages, however, only by way of dermatological prescription .
- composition of the invention with its use of selenium sulfide can provide similar benefits for treating other skin complaints, conditions and afflictions— as with antibacterial agents, anti-acne agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, and others.
- selenium sulfide such other discreet erythema as acne and sunburn can be effectively reduced as well.
- the composition of the invention is to be administered topically by a vehicle or earner medium compatible with application to the skin.
- a useful regimen would be to a) mix 1 % selenium sulfide with 3 ml of cocoa butter cream; b) apply it to the area of concern; and c) leave the blended mixture for 2-3 minutes at the area of application.
- the composition will be seen to be highly effective in reducing the flushness and redness caused by Rosacea.
- the selenium sulfide is employed as the sole active agent in the composition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A method for the treatment of Rosacea and skin erythema using selenium sulfide as an active ingredient in a topically applied administration to a user's skin.
Description
METHOD AND TOPICAL COMPOSITION FOR THE TREATMENT OF
ROSACEA AND SKIN ERYTHEMA USING SELENIUM SULFIDE
CROSS-REFERENCE TO RELATED APPLICATIONS
None.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
None.
REFERENCE TO A MICROFICHE APPENDIX
None.
BACKGROUND OF THE INVENTION
FIELD OF THE INVENTION
This invention relates to the treatment of Rosacea and skin erythema, in general, and to a method utilizing a topical composition employing selenium sul fide of different concentrations depending on the severity and extent of user symptoms, in particular.
DESCRIPTION OF THE RELATED ART
Rosacea is a very common red, acne-like benign skin condition that affects approximately 45 million people worldwide. Its main symptoms include red or pink facial skin, small dilated blood vessels, small red bumps sometimes containing pus, cysts, and pink or irritated eyes. Characteristically involving the central region of the face (mainly the forehead, the cheeks, the chin, and the lower half of the nose), Rosacea is considered a chronic, long-term incurable skin condition with periodic ups and downs. Tending to occur more frequently in women, but more severely in men, Rosacea strikes both at potentially all ages. Unfortunately, emotional factors such stress, fear, anxiety and embaiTassment have been determined to aggravate the condition.
While lacking evidence that Rosacea can be spread by contact with the skin, the sharing of towels, or through inhalation, left untreated, the condition tends to worsen over time. Often being mistaken for acne, an allergic reaction, or other skin problems, its signs and symptoms may flair up for a period of weeks to months, and then diminish before flaring up again. Often aggravated by flushing, the redness in Rosacea may cause small blood vessels in the face to enlarge permanently and become more visible through the skin, appearing like tiny red lines. Continual or repeated episodes of flushing and blushing may promote inflammation, causing small red bumps often resembling teenage acne.
While not considered contagious or infectious— and even not necessarily requiring treatment i f the individual is not bothered by the condition— many treatment choices are available depending on the severity and extent of symptoms. Antibacterial washes, topical medications, oral antibiotics, lasers, pulsed-light therapies, photodynamic therapy, and isotretinoin have oftentimes been utilized— with varying degrees of success and commensurate costs. Combination uses of them are not uncommon, with some being utilized alternatingly in the morning and at night, and others, such as with topical medications, more than once or twice a day. With metronidazole topical antibiotic medication (Rosadan®) and Azelaic Acid (Finacea®) costing in prescription amounts by dermatologists of $300.00 and more, it would be advantageous to have a simple phaiTnaceuticai composition to effectively overcome the flushing and redness in the case of Rosacea, which is not yet achievable by the use of available treatments at a less expensive cost.
As will be understood, the same holds true for skin erythema, in general.
OBJECTS OF THE PRESENT INVENTION
It is an object of the present invention, therefore, to provide an effective composition for the treatment of Rosacea.
It is an object of the present invention, also, to provide such a composition which is both
easy to apply, and which can be obtained at a more affordable price.
It is an additional object of the invention to provide such a composition which for mi ld i nstances of Rosacea may be obtained over-the-counter, without the need for prescription.
It is a further object of the invention to provide a composition of greater concentration for a more resistant condition of Rosacea, obtainable by prescription.
It is yet a further object of the present invention to provide such a composition for treating other conditions of the skin characterized by redness (i.e. skin erythema), and either as a gel, cream or lotion.
SUMMARY OF THE INVENTION
As will become clear from the following description, the objects of the present invention are achieved through the employment of selenium sulfide as an active ingredient in the method of treatment of Rosacea. As will be understood by those skil led in the art, having the chemical formula SS , and also available as selenium disulfide S S , and selenium hexasiilfide S S , e' e 2 e &' selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis. In such respects, selenium sul fide has been shown to be one in a class of anti -infectives that slow the growth of yeast which can lead to itching and flaking of the scalp. In a tested embodiment of the invention, selenium sulfide is combined with a cocoa butter moisturizer carrier in the treatment of the Rosacea. In a preferred embodiment, the selenium sulfide is employed as the sole active ingredient in the treatment.
DETAILED DESCRIPTION OF THE INVENTION
Selenium sulfide is currently employed in a concentration of 1 % i n such dandruff shampoos as Seisun Blue®, Exsel® lotion shampoo, Glo-Sel®, and Head & Shoulders®
Intensive Treatment. It is used with wann water to be massaged as a lather into the hair and scalp, being typically used once per day, or at least two times per week as directed by the user's physician.
In accordance with the present invention, and through clinical type observations, it has been determined that a topical application utilizing selenium sulfide is effective in signi ficantly reducing the redness, flushing and inflammation associated with the chronic, incurable adult acne-like skin condition of Rosacea— and with skin erythema, in general.
The composition of the invention may comprise all pharmaceutical forms for administration including solutions, gels, lotions and creams— as well as ointments, foams, emulsions, micro-emulsions, milks, serums, aerosols, sprays, dispersions, micro-capsules and micro-particles thereof. Acceptable carriers for the selenium sulfide are those suitable for topical applications for the skin, will not cause any safety or toxicity concerns, and wi l l be compatible with the selenium sulfide. One such earner employed successfully with the selenium sulfide has been found to be cocoa butter, an edible vegetable fat extracted from the cocoa bean. A ratio of about 3 parts cocoa butter to 1 part selenium sulfide provided almost optimum results in effectiveness to decrease the erythema resulting from Rosacea. Also utilizable as soaps and cleansing bars, a 1 % concentration of selenium sulfide ingredient has been approved by the FDA for cover-the-counter sales— and thus more readily obtainable, and at a lesser cost than other prescription medications used to treat these skin conditions. Effective in most instances of Rosacea, more resistant situations can be resolved by increasing the selenium sulfide concentrations to 2%, 3% or 4% levels; obtainable in the later percentages, however, only by way of dermatological prescription . Whether supplemented with known bases such as excipients, binders, lubricants and disintegrants— or with selected oily materials or emulsifying agents— the treatment with this composition has been noted to be effective in a simple one step application process. In fact, analysis has indicated that the composition of the invention with its use of selenium sulfide can provide similar benefits for treating other skin complaints, conditions and afflictions— as with antibacterial agents, anti-acne agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, and others. As such, with the selenium sulfide, such other discreet erythema as acne and sunburn can be effectively reduced as well.
In clinical type observations, the redness, small di lated blood vessels and small red bumps characterizing Rosacea have been observed to be decreased in a manner akin to the controlling of those spots found on the skin which appear from conditions known as Tinea Capitis (a fungal form of ringworm most commonly affecting children, causing itchy scalp and loss of hair in the affected areas) and Tinea Versicolor (a fungal itchy and scaly spotting lighter than the surrounding skin). There, fungi germs living on the tissue of the outer skin layers tend to spread easi ly, but whose growth is kept under reasonable control through the topical application of selenium sulfide. Treatment of dermatophyte fungal infections also with oral antifungal agents in more pronounced cases have been known to recognize the acceptance of selenium sulfide as a preventative— and in accordance with the teachings of the present invention, have been found to extend further into the area of controlling the effects of Rosacea.
In usage, the composition of the invention is to be administered topically by a vehicle or earner medium compatible with application to the skin. A useful regimen would be to a) mix 1 % selenium sulfide with 3 ml of cocoa butter cream; b) apply it to the area of concern; and c) leave the blended mixture for 2-3 minutes at the area of application. The composition will be seen to be highly effective in reducing the flushness and redness caused by Rosacea. In a preferred embodiment of the invention, the selenium sulfide is employed as the sole active agent in the composition.
While there have been described what are considered to be preferred embodiments of the present invention, it will be readily appreciated by those skilled in the art that modifications can be made without departing from the scope of the teachings herein. For at least such reason, therefore, resort should be had to the claims appended hereto for a true understanding of the scope of the invention.
Claims
1. A method of treating erythema resulting from Rosacea in a subject comprising administering topically to the skin of said subject a composition comprising about 20% to about 30% of selenium sulfide as an active agent for treating the erythema resulting from Rosacea, wherein said selenium sulfide is effective to decrease the erythema resulting from Rosacea.
2. The method of Claim 1 wherein said composition is selected from solutions, gels, lotions, creams, ointments, foams, emulsions, micro-emulsions, milks, serums, aerosols, sprays, dispersions, micro-capsules and micro-particles thereof.
3. The method of Claim 1 wherein said composition is selected from soaps and cleansing bars.
4. The method of Claim 1 wherein said composition is a cream.
5. The method of Claim 1 wherein said composition is a gel.
6. The method of Claim 1 wherein said composition is a lotion.
7. The method of Claim 1 wherein said composition comprises selenium sul fide of 1% to about 4% concentration.
S. The method of Claim 1 wherein said composition further comprises about 25% of a carrier.
9. The method of Claim 8 wherein said carrier comprises a cocoa butter emulsion.
10. The method of Claim 1 wherein said composition employs selenium sulfide as the sole active agent for treating the erythema.
1 1. The method of Claim 10 wherein said composition is selected from solutions, gels, lotions, creams, ointments, foams, emulsions, micro-emulsions, milks, serums, aerosols, sprays, dispersions, micro-capsules and micro-particles thereof.
12. The method of Claim I I wherein said composition comprises selenium sulfide of 1 % to about 4% concentration.
13. The method of Claim 12 wherein said composition further comprises about 25% of a carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/018146 WO2016137513A1 (en) | 2015-02-27 | 2015-02-27 | Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/018146 WO2016137513A1 (en) | 2015-02-27 | 2015-02-27 | Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016137513A1 true WO2016137513A1 (en) | 2016-09-01 |
Family
ID=56788952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/018146 WO2016137513A1 (en) | 2015-02-27 | 2015-02-27 | Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016137513A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258183A (en) * | 1991-08-01 | 1993-11-02 | Grimberg Georges Serge | Medicine based on neutralized sulphur derivatives |
| US5674539A (en) * | 1994-12-09 | 1997-10-07 | Tomas; Robert E. | Method of treating skin and composition |
| US20090068128A1 (en) * | 2007-09-10 | 2009-03-12 | Waddington Tauna A | Scar and rosacea and other skin care treatment composition and method |
| US20110217249A1 (en) * | 2010-03-03 | 2011-09-08 | Frank Dreher | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds |
-
2015
- 2015-02-27 WO PCT/US2015/018146 patent/WO2016137513A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258183A (en) * | 1991-08-01 | 1993-11-02 | Grimberg Georges Serge | Medicine based on neutralized sulphur derivatives |
| US5674539A (en) * | 1994-12-09 | 1997-10-07 | Tomas; Robert E. | Method of treating skin and composition |
| US20090068128A1 (en) * | 2007-09-10 | 2009-03-12 | Waddington Tauna A | Scar and rosacea and other skin care treatment composition and method |
| US20110217249A1 (en) * | 2010-03-03 | 2011-09-08 | Frank Dreher | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500261A (en) | Epidermal release composition with anti-allergic and anti-inflammatory effects | |
| CN111936130B (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| US20160199405A1 (en) | Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Selenium Sulfide | |
| BR102017003313B1 (en) | ANTI-DANDRUFF COMPOSITION AND METHOD FOR THE PREVENTION, REDUCTION OR TREATMENT OF DANDRUFF | |
| US9987304B2 (en) | Method and topical composition for the treatment of Rosacea and skin erythema using selenium sulfide | |
| US20080267899A1 (en) | Plant extract composition for hair growth | |
| WO2016137513A1 (en) | Method and topical composition for the treatment of rosacea and skin erythema using selenium sulfide | |
| US20180256596A1 (en) | Method and topical composition for the treatment of rosacea and skin erythema using pyrithione zinc | |
| US20070207115A1 (en) | Tea Tree Oil and Benzoyl Peroxide Acne Treatment | |
| Pingale et al. | A review on alopecia and its remedies | |
| WO2016137516A1 (en) | Method and topical composition for the treatment of rosacea and skin erythema using pyrithione zinc | |
| US20170173042A1 (en) | Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Pyrithione Zinc | |
| US20160199384A1 (en) | Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Pyrithione Zinc | |
| US20200330429A1 (en) | Method of treating truncal acne with trifarotene | |
| Buckley | Seborrhoeic Dermatitis (SD) | |
| RU2715719C1 (en) | Lotion for external use | |
| Chovatiya et al. | Putting the formulation back in foam: optimizing seborrheic dermatitis treatment across diverse hair types | |
| JPWO2019002421A5 (en) | ||
| JP6175067B2 (en) | New use of neohesperidin | |
| Nasser et al. | Seborrheic Dermatitis: Exploring the Pathogenesis, Clinical Features, And Treatment Strategies | |
| Puchkan et al. | Research of the market of precautions for external application for the treatment of seboreic dermatitis | |
| Bhujbal et al. | Review on Skin Disease Seborrheic Dermatitis Along With Its Treatment and Formulary | |
| US20200338019A1 (en) | Topical formulations containing vitamin a and uses thereof | |
| Buckley | Papulo-Pustular Rashes on the Face | |
| Starova et al. | The safety and efficacy of ciclopirox olamine for the treatment of seborrheic dermatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15883604 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15883604 Country of ref document: EP Kind code of ref document: A1 |